Cannabinoids cool the intestine
- 1 July 2004
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 10 (7) , 678-679
- https://doi.org/10.1038/nm0704-678
Abstract
Cannabinoids inhibit motility and secretion in the intestine. They are now assigned the additional task of curbing excessive inflammation, suggesting that drugs targeting the endogenous cannabinoid system could be exploited for inflammatory bowel disease.Keywords
This publication has 17 references indexed in Scilit:
- Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometryJournal of Lipid Research, 2004
- Involvement of cannabinoid receptors in gut motility and visceral perceptionBritish Journal of Pharmacology, 2004
- Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMNJournal of Leukocyte Biology, 2003
- Lipopolysaccharide Induces Anandamide Synthesis in Macrophages via CD14/MAPK/Phosphoinositide 3-Kinase/NF-κB Independently of Platelet-activating FactorJournal of Biological Chemistry, 2003
- Role of cannabinoid CB1 receptors and tumor necrosis factor‐α in the gut and systemic anti‐inflammatory activity of SR 141716 (Rimonabant) in rodentsBritish Journal of Pharmacology, 2003
- Anti-TNF-α therapies: the next generationNature Reviews Drug Discovery, 2003
- Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharideGlia, 2002
- Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammationBritish Journal of Pharmacology, 2001
- Mast cells are an important cellular source of tumour necrosis factor α in human intestinal tissueGut, 1999
- Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amidesNature, 1996